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Abstract
Background—Chronic infection with the hepatitis C virus (HCV) is a leading cause of global
morbidity and mortality. While recent advances in antiviral therapy have led to significant
improvements in treatment response rates, only a minority of infected patients is treated. Multiple
barriers may impede the delivery of HCV therapy.
Aim—To identify perceived barriers to care, knowledge, and opinions among a global sample of
HCV treatment providers.
Methods—An international, multidisciplinary survey of HCV treatment providers was
conducted. Each physician responded to a series of 214 questions concerning his or her practice
characteristics, opinions regarding the state of HCV care, knowledge regarding HCV treatment,
and perception of treatment barriers.
Results—697 physicians from 29 countries completed the survey. Overall, physicians viewed
patient-level barriers as most significant, including fear of side effects and concerns regarding
treatment duration and cost. There were distinct regional variations, with Central and Eastern
European physicians citing government barriers as most important. In Latin America, the Middle
East, and Africa, payer-level barriers, including lack of treatment coverage, were prominent.
Overall, the perception of barriers was strongly associated with physician knowledge, experience,
and region of origin, with the fewest barriers reported by Nordic physicians and the most reported
by Middle Eastern and African physicians. Globally, physicians demonstrated deficits in basic
treatment principles, including the role of viral kinetics and the management of treatment non-
responders. Two-thirds of surveyed physicians believed that patients do not have adequate access
to providers in their community.
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Conclusion—Barriers to HCV treatment vary globally, though patient-level factors are viewed
as most significant by treating physicians. Efforts to improve awareness, education, and specialist
availability are needed.
Keywords
Hepatitis C/therapy; health services accessibility; health care surveys; physician’s practice
patterns; delivery of health care
Introduction
Hepatitis C virus (HCV) infection affects between 130 million and 170 million persons
worldwide, is a leading indication for liver transplantation, and contributes to 350,000
deaths each year.(1) HCV is a potentially curable disease, with the majority of treated
patients now afforded the promise of a sustained virologic response (SVR).(2–5)
Unfortunately, less than half of HCV infected persons are aware of their diagnosis, and
among those with known infection, only 1% to 30% will receive treatment.(6–11)
Multiple factors serve as impediments to the delivery of antiviral therapy. These barriers
may arise at the patient, provider, payer, and/or government level.(12) Patients cite fear of
treatment-related side effects, lack of symptoms, financial constraints, and social
stigmatization as primary reasons for declining therapy.(13–16) Physicians may fail to refer
patients for subspecialty evaluation or may place undue emphasis on purported
contraindications.(17) As a result, more than 70% of patients are deemed ineligible for
treatment based on psychiatric disease, substance use, or medical comorbidities,(6, 7)
despite evidence that these factors are not absolute.(18, 19) A lack of available and
competent specialists may further interfere.(20, 21) Finally, limitations in funding, medical
coverage, and office staffing may prevent treatment.(11, 22)
Increasingly, hepatitis C is recognized as a global health crisis, demanding an international,
coordinated emphasis on promotion, prevention, and treatment.(23) To inform these
initiatives, we surveyed an international sample of HCV treatment providers, with a goal of
assessing knowledge, opinions toward HCV therapy, and perceived barriers to care.
Methods
An international, mixed-mode survey study of HCV treatment providers was conducted in
December 2010 with an aim to identify physician and practice characteristics, opinions
regarding HCV care, knowledge of treatment principles, and perceived barriers to care. A
214-item questionnaire was developed by the International Conquer C Coalition (IC3), an
organization of hepatitis C experts formed with the goal of optimizing global HCV care. The
questionnaire was piloted by a 67-member focus group of IC3 members. Physicians were
considered eligible for the study if they treated a minimum of 10 HCV patients each month
and if they resided in one of the 8 predetermined global regions: United States, Canada,
Latin America, Western Europe, Central/Eastern Europe, Nordic, Asia/Pacific, and Middle
East/Africa. Target respondents included hepatologists, gastroenterologists, infectious
disease physicians, internists, and general practitioners. The survey was distributed to a
sample of 1400 physicians identified via an international market research database(24) and
was administered by 25-minute phone interview or internet based format by a professional
survey company (Phoenix Marketing International, Rhinebeck NY). Participants were asked
a series of open-ended, multiple-response, and Likert scale questions. Translation was
provided for non-English speaking participants. Each participant received a modest
honorarium for completing the survey. All responses were anonymous.
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Physician/Practice Characteristics and Opinions Regarding HCV Care
Each physician was asked about his or her medical specialty, practice location, patient
volume, and patient characteristics. Opinions regarding the current state of HCV care were
assessed according to level of agreement with the following statements: (1) national
treatment guidelines are available in my country; (2) treatment guidelines and policies are
consistent among professional societies, payers, and government; (3) government and/or
payers recognize national or international treatment guidelines; (4) healthcare providers
have knowledge of screening and treatment guidelines; (5) the general public is aware of
HCV; (6) patients understand the consequences of HCV if it is not treated; (7) most patients
are aware that HCV is curable; (8) patients have adequate access to HCV providers in their
community; responses were rated on a 10-point Likert scale, with 0 representing “strongly
disagree,” 5 “neither agree nor disagree,” and 10 “strongly agree.”
Knowledge
Physician knowledge was assessed according to level of agreement with the following eight
statements: (1) the addition of ribavirin to peginterferon improves the likelihood of SVR; (2)
maintaining an optimal dose of ribavirin with interferon is necessary to achieve an SVR; (3)
different viral genotypes require different treatment durations; (4) treatment should be
discontinued for patients who fail to achieve a 2-log decrease in HCV RNA by treatment
week 12; (5) treatment should be discontinued for patients who have detectable HCV RNA
at treatment week 4; (6) patients with stage 1 fibrosis have worse treatment outcomes than
patients with stage 4 fibrosis; (7) the level of HCV RNA has no correlation with the severity
of liver disease; (8) maintenance therapy should be prescribed for treatment non-responders.
Each response was rated on a 10-point Likert scale, with 0 representing “strongly disagree,”
5 representing “neither agree nor disagree,” and 10 representing “strongly agree.”
Barriers to Care
The main focus of this study was to assess perceived barriers to HCV care. Each respondent
was presented with 31 potential barriers categorized by patient, provider, government, and
payer related categories (Table I). Responses were based on a 10-point Likert scale, with 0
representing “not a barrier to treatment,” 5 representing “somewhat of a barrier to
treatment,” and 10 representing “large barrier to treatment.”
Statistical Analysis
The mean, range, standard deviation, and shape of the distribution were examined for each
continuous variable, with frequencies tabulated for each categorical variable. Physician and
practice characteristics were compared across global regions using Pearson’s Chi-square test
for categorical variables and one-way analysis of variance for continuous variables.
Bivariable analysis was used to examine the relationship between physician/practice
characteristics and perceived barriers to care, using Pearson’s correlation analysis for
continuous independent variables and one-way analysis of variance for each categorical
independent variable. Multiple linear regression was used to identify characteristics
independently associated with perceived barriers to care. All analyses were performed using
Stata 11 (College Station, TX).
Results
A total of 697 physicians were surveyed across 8 global regions, representing 29 individual
countries (Supplemental material: Figure I). The overall response rate was 50%. Physician
and practice characteristics are summarized in Table II. Overall, physicians were in practice
for a mean of 16 years and treated an average of 46 HCV patients each month (range: 5 to
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500 patients). Physician specialty varied by region, with HCV care more commonly
provided by hepatologists and gastroenterologists in the United States and Western Europe,
by infectious disease specialists in Central/Eastern Europe, and by internists or general
practitioners in remaining regions. Physicians most frequently worked in a private, urban
facility, though a government-affiliated practice was most common in Central/Eastern
Europe and Nordic regions. Dedicated treatment nurses and/or assistants were more
frequently employed in European countries. Source of medical coverage varied
significantly, with patients in Europe, Canada, and Asia/Pacific regions covered primarily
by public insurance. A mix of public and private coverage was seen in the United States and
Latin America. More than one-third of patients in the Middle East and Africa were
reportedly uninsured. Overall, approximately one-quarter of patients were reported to refuse
therapy, with the highest refusal rate in Asia/Pacific countries and the lowest in Nordic
countries (37% vs. 14%, p<.0001).
Opinions Regarding HCV Care
Physician opinions regarding the current state of HCV care are shown in Table III. The
majority of physicians indicated that national treatment guidelines existed in their country;
however, less than half felt that guidelines were consistent across sources. Only 36% to 38%
of physicians in North America, Latin America, and Middle East/Africa believed that
government and/or payers recognized treatment guidelines, compared to 71% to 83% in
European countries. Between 20% and 54% of respondents felt that healthcare providers
have adequate knowledge of HCV guidelines, with higher levels of agreement across
European countries. Globally, less than one-quarter of physicians felt that the general public
is aware of HCV and know that it is a curable disease. Only 35% of all surveyed physicians
believed that patients have adequate access to HCV treatment providers, with the lowest
percentage in the United States (17%) and the highest in Nordic countries (62%).
Knowledge
Knowledge of HCV treatment principles varied significantly by region, with physicians in
Western Europe correctly answering the most knowledge questions, and those in Middle
East and African countries correctly answering the fewest (6.4 vs. 3.2, p<0.001; Figure Ia).
Overall, physicians understood that ribavirin is a necessary component of treatment, that
treatment duration varies by genotype, and that treatment should be discontinued for patients
who fail to achieve an early virologic response (EVR). However, a majority of physicians
incorrectly believed that HCV RNA level correlates with liver disease severity and that
treatment non-responders should receive maintenance therapy (Table IV). In Middle East/
African countries, a majority of respondents also did not appreciate the importance of
ribavirin, the role of HCV viral kinetics, and the significance of liver fibrosis stage.
Globally, knowledge was highest among hepatologists and lowest among general
practitioners (p<0.001 for overall comparison; Figure Ib). Source of treatment information
varied by region, with national and government guidelines used most frequently in all
regions except the in the United States, where guidelines from the American Association for
the Study of Liver Diseases (AASLD) were most commonly used (Supplemental material:
Figure II).
Barriers to Care
There was significant regional variation in perceived barriers to care, with the greatest
barriers reported in Middle East/Africa and the fewest in Nordic countries (Figure IIa;
p<0.0001 for overall comparison). Globally, patient-related barriers were viewed as most
significant, representing the highest rated barrier category in 5 out of 8 regions, including
the United States (Figure IIb). Specific patient-related barriers included fear of side effects
and concerns regarding treatment duration, cost, and effectiveness (Supplemental Table I).
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Payer-related barriers were most prominent in Latin American and Middle East/Africa and
included lack of coverage leading to out-of-pocket expense and excessive paperwork
requirements. Only one region, Central/Eastern Europe, cited government-related barriers
(insufficient funding and lack of treatment promotion) as most significant.
Along with geographic region, perceived barriers were significantly associated with
physician specialty, physician experience, practice setting, and physician knowledge (Table
V). Subspecialists (hepatology, gastroenterology, infectious diseases) reported fewer
perceived barriers than internists and general practitioners. Likewise, physicians with more
experience and higher knowledge scores reported fewer barriers. In multivariable regression
analysis, only global region, years of experience, and knowledge were significantly
associated with perceived barriers to care (Supplemental material: Table II).
Discussion
This international, multidisciplinary survey study provides insight into the current state of
hepatitis C care, as viewed by treating physicians. Key findings of our study include marked
regional variation in perceived barriers, the importance of patient-level obstacles,
concerning deficits in provider knowledge, and the shared pessimism regarding the current
state of HCV care.
Foremost, barriers to care were not perceived equally across global regions. Physicians from
Nordic and Western European countries had remarkably low perceptions of treatment
barriers (mean Likert responses of 1.7 and 2.1, respectively, on a 10-point scale). In contrast,
Middle Eastern and African physicians perceived all barrier categories as problematic (mean
Likert response: 6.1 out of 10). Despite regional differences in the magnitude of perceived
barriers, there was agreement regarding the nature of these barriers. Across all global
regions, patient-level factors were viewed as the greatest obstacles to treatment. This is
consistent with prior surveys of physicians and patients in the United States and United
Kingdom.(13, 15, 16, 22) Specifically, fear of treatment-related side effects was the most
frequently cited barrier in our study. This fear is not unfounded, as nearly all patients will
experience at least one treatment-related side effect, and 10% to 14% of patients will
discontinue treatment as a result.(2, 4) Though side effects are common, appropriate
pretreatment counseling, along with a structured plan for monitoring and management, may
help alleviate such fears.(25)
Further patient-level barriers included concerns regarding treatment duration and antiviral
effectiveness. Fortunately, the recent introduction of direct-acting antivirals offers the
potential for improved response rates and reduced treatment lengths. However, these
benefits will need to be balanced against a greater incidence of treatment-related side
effects.(4, 5) Nevertheless, each of these patient-level barriers is addressable and, in many
cases, modifiable.
To properly address patient fears, physicians must have a thorough understanding of
antiviral therapy. Unfortunately, our study identified concerning knowledge deficits, which
were most apparent in Middle East/African countries. Physicians in this region often did not
acknowledge important treatment principles, including the significance of ribavirin in HCV
therapy. Interestingly, across all regions, more than half of physicians indicated that they
would treat non-responders with maintenance interferon therapy, despite its lack of efficacy.
(26) Similarly, most physicians incorrectly believed that HCV RNA level reflects liver
disease severity. Though prior studies of healthcare providers have demonstrated significant
knowledge gaps related to HCV,(27) our study documented these deficits in experienced
HCV treaters. This is concerning, because inadequate physician knowledge is a known
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barrier to care.(20) Furthermore, independent of geographic region, medical specialty, or
experience level, physicians who scored lower on the knowledge assessment tended to
perceive greater barriers to care. The implication here is twofold: physicians with less
knowledge may treat fewer patients as a result of incorrectly perceived barriers, and these
perceived barriers may be overcome through improved education.
Recognizing the current deficits in physician knowledge, the Institute of Medicine recently
recommended the development of HCV educational initiatives, emphasizing a need for
increased awareness and improved adherence to guidelines.(28) In our study, only 40% of
respondents believed that providers have adequate knowledge of treatment guidelines,
highlighting this need. Physicians held similar views regarding public awareness, with less
than one-quarter of respondents believing that the public is aware of HCV and its
consequences. This view is supported by findings from the National Health and Nutrition
Examination Survey (NHANES), in which more than half of HCV-infected persons were
unaware of their diagnosis.(29) Among injection drug users, this number is as high as 72%
to 90%.(30, 31) Unfortunately, awareness does not guarantee treatment. In our study, only
35% of physicians believed that patients have adequate access to HCV providers. A lack of
trained specialists, combined with their concentration at academic medical centers, may
limit the widespread availability of treatment. Indeed, market surveys in the United States
indicate that 80% of HCV patients are managed by 20% of gastroenterologists.(21) Models
of expanded HCV treatment, including the use of tele-health, have shown promise.(32)
These warrant broader exploration and implementation.
This is the first international study to examine barriers to care among HCV treatment
providers. The findings are strengthened by a comprehensive questionnaire, developed and
piloted by a panel of internationally recognized HCV experts. The survey achieved a 100%
item response rate, eliminating the potential for non-response bias. However, as with any
survey, the findings in our study may not be representative of the entire population.
Likewise, it was not feasible to survey physicians within every country, leading to the
potential for coverage error. By grouping our findings into global regions, we may not have
adequately addressed the differences that exist between individual countries. Further, the
perceptions identified in this study may not be representative of less-experienced physicians.
This may have led to an underestimation of treatment barriers. Finally, HCV treatment is
frequently delivered by mid-level providers (nurse practitioners and physician assistants),
particularly in the United States. This study did not address the perspective of these
providers, which may differ from those of physicians.
Still, the findings of this study highlight the significant barriers that may impede the prompt
and appropriate treatment of hepatitis C virus infection. A focus on patient and provider
education, increased awareness, and treatment promotion is necessary if progress is to be
made in the global fight against HCV infection.
Conclusions
Recent advances in antiviral therapy have produced dramatic improvements in the treatment
of hepatitis C virus infection. Unfortunately, only a minority of HCV-infected persons will
receive treatment due to multiple barriers to care. Globally, physicians cite patient-level
factors, including fear of side effects and concerns regarding treatment duration and cost, as
the greatest barriers to treatment. Inadequate physician knowledge and limited specialist
availability may further contribute. Efforts to improve patient and physician education,
public awareness, and access to treatment providers are needed.
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Figure 1. Knowledge of HCV Treatment Principles
Physician knowledge by global region (Panel A) and medical specialty (Panel B).
US, United States; CAN, Canada; LAT, Latin America; WE, Western Europe; CEE,
Central/Eastern Europe; NOR, Nordic; AP, Asia/Pacific; MEA, Middle East/Africa;
Hepatol, hepatology; GI, gastroenterology; ID, infectious diseases; IM, internal medicine;
GP, general practice
*Correct responses indicated by a Likert rating of 6 or higher on the 10-point scale for each
of 8 knowledge questions
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Figure 2. Barriers to HCV Treatment
A. Barriers by Global region: mean (SD) Likert response to each of 31 potential barriers,
by region.
B. Regional Barriers by Category: mean (SD) Likert response to each barrier category, by
region.
US, United States; CAN, Canada; LAT, Latin America; WE, Western Europe; CEE,
Central/Eastern Europe; NOR, Nordic; AP, Asia/Pacific; MEA, Middle East/Africa
*Each barrier rated on a 10-point Likert scale, from 0 “not a barrier” to 10 “large barrier.”
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Table 1
Perceived Barriers to HCV Treatment
Patient-related
• Fear of side-effects
• Medication expense
• Laboratory expense
• Low success rate of treatment
• Fear of stigma related to HCV
• Preference for alternative therapy
• Desire to wait for newer therapies
• Difficulty with administration
• Treatment duration
• Patient declines liver biopsy
• Inaccessibility of experienced providers
Government-related
• Government restricts treatment
• Insufficient funds allocated to HCV
• Lack of promotion for HCV treatment
Provider-related
• Treatment limited to government-mandated centers
• Lack of office infrastructure to treat patients
• Insufficient reimbursement for physicians
• Unable to obtain necessary labs for treatment
• Limited access to medications or labs
• Insufficient training for HCV management
• Lack of referral to HCV providers by other physicians
• Lack of proper storage for medications
Payer-related
• Insurance plan does not cover treatment
• High out-of-pocket expense for patients
• Restricted insurance coverage for patients with HCV
• Insurance plans will not cover RNA/genotyping
• Excessive paperwork requirements
• Insurance plans limit which physicians treat HCV
• Insurer does not cover serum markers of fibrosis
• Insurance plans do not cover medications for side-effects
• Liver biopsy required for treatment
All barriers scored on a 10-point Likert scale, with 0 representing “not a barrier to treatment,” 5 representing “somewhat of a barrier to treatment,”
and 10 representing “large barrier to treatment”
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Table 5
Bivariable Associations Between Physician/Practice Characteristics and Perceived Barriers to Care
Characteristic n Mean Barrier Score
§
 or Correlation P value*
Global Region
  United States 102 4.4 <0.0001
  Canada 30 3.6
  Latin America 100 4.8
  Western Europe 103 2.1
  Central/Eastern Europe 101 3.2
  Nordic 52 1.7
  Asia/Pacific 108 4.6
  Middle East/Africa 101 6.3
Specialty
  Hepatology 129 3.4 <0.0001
  Gastroenterology 176 3.8
  Infectious Diseases 194 3.8
  Internal Medicine 83 4.6
  General Practice 115 5.1
Years in Practice 697 −0.26 <0.0001
Patients seen monthly 697 0.02 0.67
Practice Location
  Urban 599 4.0 0.49
  Rural/Suburban 98 4.2
Practice Setting
  Private 298 4.5 <0.0001
  University/Academic 183 3.4
  Government 182 3.9
  Other 34 4.1
Knowledge Score 697 −0.40 <0.0001
§
Mean response to each of 31 barrier questions, rated on a 10-point Likert scale.
*
Means and p values based on one-way analysis of variance for categorical variables; Correlations and p values based on Pearson’s correlation
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